托珠单抗
美罗华
医学
内科学
耐火材料(行星科学)
改良兰金量表
不利影响
肿瘤科
淋巴瘤
疾病
天体生物学
物理
缺血
缺血性中风
作者
Woojin Lee,Sang Kun Lee,Jangsup Moon,Jun‐Sang Sunwoo,Jung Ick Byun,Joo Hyun Lim,Tae Joon Kim,Yeong-Gil Shin,Keon Joo Lee,Ji Hae Jun,Han Sang Lee,Soyun Kim,Kyung‐Il Park,Keun Hwa Jung,Ki Young Jung,Manho Kim,Sang Kun Lee,Kon Chu
标识
DOI:10.1007/s13311-016-0442-6
摘要
A considerable portion of autoimmune encephalitis (AE) does not respond to conventional immunotherapies and subsequently has poor outcomes. We aimed to determine the efficacy of tocilizumab, an anti-interleukin-6 antibody, in rituximab-refractory AE compared with other treatment options. From an institutional cohort of AE, 91 patients with inadequate clinical response to first-line immunotherapy and following rituximab were retrospectively reviewed. Patients were grouped according to their further immunotherapy strategies. Thirty (33.0 %) patients were included in the tocilizumab group, 31 (34.0 %) in the additional rituximab group, and 30 (33.0 %) in the observation group. Outcomes were defined as the favorable modified Rankin Scale scores (≤2) at 1 and 2 months from the initiation of each treatment strategy and at the last follow-up. Favorable clinical response (improvement of the modified Rankin Scale scores by ≥ 2 points or achievement of the mRS scores ≤ 2) at the last follow-up was also analyzed. The tocilizumab group showed more frequent favorable mRS scores at 2 months from treatment initiation and at the last follow-up compared with those at the relevant time points of the remaining groups. The majority (89.5 %) of the patients with clinical improvement at 1 month from tocilizumab treatment maintained a long-term favorable clinical response. No serious adverse effects of rituximab or tocilizumab were reported. Therefore, we suggest that tocilizumab might be a good treatment strategy for treating AE refractory to conventional immunotherapies and rituximab. The tocilizumab-mediated clinical improvement manifests as early at 1 month after treatment initiation.
科研通智能强力驱动
Strongly Powered by AbleSci AI